MedHub-AI Announces National Reimbursement Approval in Japan for AutocathFFR™
TEL AVIV, Israel, Oct. 3, 2025 /PRNewswire/ -- MedHub-AI today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company's AutocathFFR™ System, effective October 1, 2025. The decision follows regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this year and marks a...
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, TREM2 H157Y, significantly increases the risk of Alzheimer's disease (AD) in individuals of ethnic Chinese descent. The research reveals that this variant confers a risk level comparable to that of the strongest...
SI GROUP BUILDS EMEA DISTRIBUTION NETWORK THROUGH NEW PARTNERSHIP WITH AZELIS
New collaboration will expand SI Group's customer reach complementing its long-standing partnership with Brenntag THE WOODLANDS, Texas, Oct. 2, 2025 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today a new partnership with Azelis to expand its EMEA distribution...
Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as the reference product ACTEMRA® (tocilizumab) AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the FDA This launch strengthens Celltrion's immunology portfolio beyond tumor-necrosis factor (TNF)-alpha and interleukin (IL)-12...
AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing
Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA Damage Response ("DDR") therapeutic product candidate, targeting the previously undruggable target ILF2, inducing synthetic lethality in DDR and Homologous Recombination Deficiency...
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3 MSA is a rare, rapidly progressing, neurodegenerative disease with no approved treatments available4,5 The innovative design of the pivotal MASCOT trial aims to accelerate...
ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer’s Disease
BOSTON, Oct. 2, 2025 /PRNewswire/ -- Addressing Critical Unmet Medical Need ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's therapeutics are limited to slowing cognitive decline, but the company's preclinical data demonstrates something fundamentally different – the ability to reverse brain damage...
Kolmar Korea Presents “K-Beauty Success Roadmap” in Amazon Beauty in Seoul
Official manufacturing sponsor of Amazon Beauty in Seoul 2025, attracting over 3,000 online and offline participants Vice Chairman Sang-Hyun Yoon emphasizes the evolution toward blockbuster products as the key driver of K-Beauty's global success SEOUL, South Korea, Oct. 1, 2025 /PRNewswire/ -- Kolmar Korea, a leading global ODM(Original Development Manufacturing)...
Vatech Launches ‘Boundless Campaign’ to Eliminate Barriers in Dental Care
First milestone: reduced device operation time update eases discomfort for elderly and disabled patients SEOUL, South Korea, Oct. 1, 2025 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global leader in dental imaging solutions, today announced the launch of its 'Boundless Campaign' a long-term initiative aimed at creating a world where no one is...
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
HYDERABAD, India, Oct. 1, 2025 /PRNewswire/ -- Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad. This collaboration aims to bring high-value, next-generation sequencing (NGS) technologies closer to patients and healthcare providers...
